title: 18F FDG PET/CT and Head and Neck Cancer: Patient Management and Outcomes.
abstract: There is a growing body of evidence that point to the value of 18F fluoro-deoxyglucose-PET/CT in the management of head and neck cancer (HNC) patients and predicting patient-related outcomes. FDG-PET/CT changes the baseline staging (compared with CT or MR imaging), guides appropriate therapy selection, separates the responders and non-responders for therapy assessment, adds value to clinical assessment in follow-up, and predicts patient survival outcomes. FDG-PET/CT can identify the recurrences in earlier stages and individualize follow-up regimens in HNC patients. This article reviews the value of FDG-PET/CT in management strategy and survival outcome of HNC patients.
authors.affiliation: Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, JHOC 3230, 601 North Caroline Street, Baltimore, MD 21287, USA.
authors.forename: Sara
authors.initials: S
authors.lastname: Sheikhbahaei
authors.affiliation: Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, JHOC 3230, 601 North Caroline Street, Baltimore, MD 21287, USA.
authors.forename: Charles
authors.initials: C
authors.lastname: Marcus
authors.affiliation: Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, JHOC 3230, 601 North Caroline Street, Baltimore, MD 21287, USA; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 601 North Caroline Street, Baltimore, MD, USA; Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, 624 North Broadway, Baltimore, MD 21205, USA. Electronic address: rsubram4@jhmi.edu.
authors.forename: Rathan M
authors.initials: RM
authors.lastname: Subramaniam
mesh_terms: D002294:Carcinoma, Squamous Cell / Q000000981:diagnostic imaging*; D019788:Fluorodeoxyglucose F18; D006258:Head and Neck Neoplasms / Q000000981:diagnostic imaging*; D006801:Humans; D064847:Multimodal Imaging / Q000379:methods; D049268:Positron-Emission Tomography / Q000379:methods*; D011446:Prospective Studies; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed / Q000379:methods*
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
keywords: Head and neck squamous cell cancer; Management change; Prognosis; Survival outcome; Therapy response